“89bio Inc. Sets the Stage for Growth: Announces Successful Pricing of $250 Million Public Offering of Common Stock and Pre-Funded Warrants”
89bio, Inc. Announces Pricing of Upsized Public Offering Introduction On January 28, 2025, 89bio, Inc. (“89bio”) made a significant announcement regarding the pricing of its upsized underwritten public offering. The clinical-stage biopharmaceutical company, focused on developing innovative therapies for liver and cardiometabolic diseases, revealed the details of the offering which includes the issuance of common…